Back to top

Image: Bigstock

Is Histogenics (HSGX) Outperforming Other Medical Stocks This Year?

Read MoreHide Full Article

Investors focused on the Medical space have likely heard of Histogenics , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of HSGX and the rest of the Medical group's stocks.

Histogenics is a member of our Medical group, which includes 841 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. HSGX is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for HSGX's full-year earnings has moved 95.03% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

According to our latest data, HSGX has moved about 56.22% on a year-to-date basis. At the same time, Medical stocks have gained an average of 3.81%. As we can see, Histogenics is performing better than its sector in the calendar year.

Breaking things down more, HSGX is a member of the Medical - Biomedical and Genetics industry, which includes 345 individual companies and currently sits at #63 in the Zacks Industry Rank. This group has gained an average of 11% so far this year, so HSGX is performing better in this area.

Going forward, investors interested in Medical stocks should continue to pay close attention to HSGX as it looks to continue its solid performance.

Published in